ALBO News and Press, Albireo Pharma Inc. From 05/07/20

Albireo Pharma (NASDAQ: ALBO ): Q1 GAAP EPS of -$2.23 misses by $0.87 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020  — — First sites initiated for second pivotal trial in biliary atresia — — Management to host conference call and webcast today at 10:00 a.m. ET — BOST...

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on May...

Shares of Mirum Pharmaceuticals ( MIRM ) have lost over a third of their value so far in 2020. To be fair, shares have doubled since lows established in Q4 of last year on the heels of a positive regulatory update for the company's lead program. It's also interesting that the current share p...

BOSTON, April 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present via webcast at the 19th Annual Needha...

Fighting cruelty with just criticism is like fighting against sword with a stick ."― Amit Kalantri It is nice to see the new trading week begin with some optimism and a big rally. Today we look at an interesting ' Tier 4 ' biotech name. A full investment analysis follows below. ...

Albireo Pharma ( ALBO -0.9% ) completes the enrollment of 47 subjects in a Phase 2 clinical trial evaluating ileal bile acid transporter (IBAT) elobixibat (5 mg) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), the first such study asses...

On track to report topline data mid-2020 BOSTON, March 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced achievement of full patient enrollment in its Phas...

BOSTON, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day 2020 and reaffirms its commitment to patients and families living with bilia...

BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Cowen and Company 40...